UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: March 2017 (Report No. 4)
Commission file number: 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant's name into English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F xForm 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ¨
This Form 6-K of the Registrant consists of the following documents, which are attached hereto and incorporated by reference herein.
This Form 6-K is incorporated by reference into the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on November 28, 2016 (Registration No. 333-214817).
| Exhibit | | |
| | | |
| 99.1 | | Notice and Proxy Statement with respect to the Registrant’s annual general meeting of the shareholders to be held on April 30, 2017, describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting. |
| | | |
| 99.2 | | Proxy Card whereby holders of ordinary shares and American Depository Shares of the Registrant may vote at the meeting without attending in person. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Cellect Biotechnology Ltd. |
| | (Registrant) |
| | |
| | By | /s/ Dr. Shai Yarkoni |
| | Name: Dr. Shai Yarkoni |
| | |
| | Chief Executive Officer |
Date: March 22, 2017
